Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16979269 | 0.84 | TRPV1 (0.54) | DRD2DRD1KDM4ECA1CA2 | |
| SCHEMBL5244479 | 0.83 | CA1 (0.55) | DRD2DRD1KDM4ESMN1; SMN2CA1 | |
| SCHEMBL6253578 | 0.82 | SLC6A2 (0.51) | DRD2DRD1KDM4ESMN1; SMN2CA1 | |
| SCHEMBL29783557 | 0.82 | PRCP (0.64) | DRD2DRD1CA1CA2CA9 | |
| SCHEMBL28942533 | 0.82 | PRCP (0.64) | DRD2DRD1CA1CA2CA9 | |
| SCHEMBL7598346 | 0.81 | SLC6A2 (0.53) | DRD2DRD1KDM4ESMN1; SMN2CA1 | |
| SCHEMBL14354453 | 0.80 | SLC6A2 (0.55) | DRD2DRD1KDM4ESMN1; SMN2 | |
| SCHEMBL5244484 | 0.78 | SMN1; SMN2 (0.52) | DRD2DRD1KDM4ESMN1; SMN2CA1 | |
| SCHEMBL4467003 | 0.78 | SLC6A2 (0.45) | DRD2DRD1KDM4ESMN1; SMN2 | |
| SCHEMBL5245716 | 0.77 | KDM4E (0.51) | DRD2DRD1KDM4ESMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9173879-B2 | Crystalline forms of (S)-7-([1,2,4]triazolo[1,5-a ]pyridin-6-yl)-4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydroisoquinoline and use thereof | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140364441-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2014-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140364441-A1 | CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF | UACA, SCN1A, NLN | DRD2 1595/4885DRD1 1128/4885KDM4E 4453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.